Imricor Announces Sales Collaboration with Optoacoustics
12.8.2020 14:00:00 EEST | Business Wire | Press release
Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR), the global leader in MRI-guided cardiac ablation products, is pleased to announce a sales collaboration with Optoacoustics Ltd, the world leader in innovative, high performance optical communication solutions for magnetic resonance (MR) applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200812005231/en/
Imricor Announces Sales Collaboration With Optoacoustics (Photo: Business Wire)
The collaboration establishes a formal relationship between Imricor and Optoacoustics to facilitate the introduction of the IMROC IRTM Wireless Multichannel Communication System to Imricor customers. IMROC provides wireless noise cancelling MRI headsets that can be used by up to 8 participants simultaneously, including the patient. The system was developed specifically for use in iCMR environments.
Given the noise and complexities of MRI, normal conversation can be difficult during iCMR procedures. The IMROC IR System is the first multichannel wireless audio system in the world to operate without RF. The system uses light waves for transmission with no impact on MRI imaging, enabling calm, clear dialog between doctors and technicians.
“Optoacoustics is a well-known company in the communication space. The technology is very innovative and supports our overall strategy of bringing cardiac interventions into the iCMR,” said Nick Twohy, Imricor’s Director of Marketing.
Imricor products are specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. Imricor is the first and only company to offer cardiac ablation devices for use in the MRI environment.
Dr. Yuvi Kahana, CEO and Co-Founder of Optoacoustics, stated, “We're thrilled and excited - it's hard to imagine a better fit for IMROC. Imricor's advances in cardiac catheter ablation highlight the productive benefits of simple, comfortable communications among iCMR staff, and IMROC provides the most effective and robust noise cancelling solution available.”
About Imricor
Please visit http://imricor.com/investors/about-imricor/ for more information about Imricor, Foreign Ownership Restrictions, and Forward-Looking Statements.
About Optoacoustics
Optoacoustics Ltd is the world’s leading provider of noise cancelling optical headphones and microphones for MRI. Please visit http://www.optoacoustics.com/medical for more information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200812005231/en/
Contact information
Investors:
Steve Wedan
Executive Chair, President and CEO
Email: steve.wedan@imricor.com
Investors & Australia Media:
Carrie Barrack
Senior Advisor, Cato & Clive
Email: carrie@catoandclive.com
Phone: +61 422 464 028
Rest of World Media:
Nick Twohy
Director of Marketing, Imricor
Email: nick.twohy@imricor.com
Phone: +1 952 818 8407
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Expands Mid-tier 5G Portfolio with New RedCap 3GPP Release 17 Variants2.3.2026 09:00:00 EET | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the expansion of its 5G RedCap portfolio with the launch of the RM255C-GL for global markets and the RG255C-NA for the North America market, further strengthening its mid-tier 5G offering for worldwide deployments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260301754857/en/ Quectel expands mid-tier 5G portfolio with new RedCap 3GPP release 17 variants As 5G expands further into industrial and IoT domains, the need for solutions that combine strong performance with cost efficiency is becoming increasingly critical. Positioned between high-speed eMBB and narrowband NB-IoT, 5G RedCap (Reduced Capability) has emerged as the ideal technology to address this mid-tier connectivity gap. With a comprehensive product portfolio and global deployment expertise, Quectel enables a seamless transition for mid-speed IoT applications moving toward sca
Thales sets a world first in quantum-safe security for 5G networks2.3.2026 09:00:00 EET | Press release
Quantum computing has the potential to break today’s encryption methods in the future, putting mobile communications, personal data and critical infrastructure at risk. For telecom operators, this is not a distant theoretical issue: 5G networks underpin everything from smartphones and connected vehicles to emergency services, industry and national infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260301594505/en/ WORLD FIRST: Thales has successfully demonstrated a world-first innovation that prepares 5G networks for the age of quantum computing, marking a major milestone for the global telecommunications industry. (credit photo 123ref) The challenge is scale. Replacing millions of devices every time security standards evolve is neither practical nor sustainable. The industry needs a new approach. With this demonstration, Thales shows that security can be upgraded remotely and instantly, directly on SIM and eSIM
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera2.3.2026 09:00:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted Priority Review for rusfertide. Rusfertide is an investigational, first-in-class hepcidin mimetic peptide therapeutic for the treatment of adults with polycythemia vera (PV). The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. In addition to Priority Review, rusfertide has received Breakthrough Therapy designation, Orphan Drug designation and Fast Track designation from the U.S. FDA. PV is characterized by the overproduction of red blood cells (erythrocytosis), which increases blood viscosity, or thickness, and can result in life threatening thrombotic events. Hematocrit is the ratio of red blood cells to the total amount of blood in the body. Achieving and maintaining controlled hematocrit levels of <45% is the primary tr
NHOA Energy Announces Two Major MACSE Battery Projects2.3.2026 09:00:00 EET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, has been awarded two new Battery Energy Storage System (BESS) projects in Italy by a leading independent platform in the renewables and energy transition sector, with a total MACSE-contracted capacity of about 600 MWh and a total power of 90 MW. The two projects, located in Campania and Sardinia, represent NHOA Energy’s first systems awarded under MACSE (Meccanismo di Approvvigionamento di Capacità di Stoccaggio Elettrico), Italy’s new capacity mechanism dedicated to long-duration storage, and a milestone in the company’s growth in the national energy storage market. The projects, financed by a pool of top-tier Italian and international financial institutions, reaffirm NHOA Energy’s centrality as technology supplier and turnkey contractor in the Italian BESS market, built on extensive local and international experience, breadth of resources, intimate understanding of standards and regulation, and awareness of the eme
Airgain and Nextivity Enter Strategic Partnership on Co-developing Next Generation Integrated 4G / 5G Solutions2.3.2026 08:30:00 EET | Press release
Airgain, Inc. (NASDAQ: AIRG), a leading provider of wireless connectivity solutions, and Nextivity, Inc., an industry leader in intelligent cellular coverage solutions, today announced they have entered into a Strategic Partnership Agreement to collaborate on the development of integrated solutions aimed at improving 4G and 5G coverage across challenging indoor and outdoor environments. The agreement establishes a structured framework for Airgain and Nextivity to jointly define and co-develop integrated coverage solutions that leverage Airgain’s Lighthouse™ 5G Intelligent Node platform and Nextivity’s GO family of intelligent repeaters powered by Nextivity’s IntelliBoost® processor to enhance 4G and 5G coverage solutions beyond the walls of a building. Large Market Opportunity & Accelerated Go‑to‑Market Execution Industry demand for intelligent 4G and 5G coverage-extension solutions continues to accelerate as operators, enterprises, and public safety organizations expand network densif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom